在中枢神经系统临床试验中解决安慰剂反应挑战的当前和新兴技术:承诺,陷和前进的途径
William P Horan1, Gary Sachs2, Dawn I Velligan3
1Dr. Horan is with Karuna Therapeutics in Boston, Massachusetts, and University of California in Los Angeles, California.
Innovations in clinical neuroscience
|March 18, 2024
概括
创新技术可能有助于降低中枢神经系统 (CNS) 药物试验中的高安慰剂反应率. 评估这些数字工具对于改善中枢神经系统研究中的治疗信号检测至关重要.
科学领域:
- 神经科学和临床药理学
- 数字健康和临床试验创新
背景情况:
- 高的安慰剂反应率在中枢神经系统 (CNS) 药物发现中构成重大障碍.
- 中枢神经系统试验的日益数字化和分散化需要探索管理安慰剂效应的新方法.
研究的目的:
- 探索创新技术在中枢神经系统临床试验中减轻安慰剂反应的潜力.
- 评估新技术和研究设计如何提高治疗信号的检测.
主要方法:
- 开发概念框架,以理解安慰剂反应.
- 对直接针对安慰剂反应的技术进行批判性评估.
- 对招聘,保留和数据收集的基于技术的方法的评估.
- 对新型远程数字表型技术的审查.
- 讨论实施这些战略的科学和监管考虑因素.
主要成果:
- 在中枢神经系统试验中,各种创新技术显示出解决安慰剂反应的前景.
- 数字化和远程评估提供了减轻安慰剂效应的潜在途径.
- 目前正在仔细评估技术干预的风险和益处.
结论:
- 技术创新有可能减轻中枢神经系统药物发现中的安慰剂反应.
- 需要进一步的研究来验证这些技术的有效性和安全性.
- 创新工具的战略选择是改善中枢神经系统试验结果的关键.
相关概念视频
01:54The Placebo Effect
6.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.2K
02:07Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
01:11Blinding
2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:28Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126